Immunome (NASDAQ:IMNM) Announces Earnings Results, Misses Estimates By $0.08 EPS

Immunome (NASDAQ:IMNM) announced its quarterly earnings data on Thursday. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08), Zacks reports. Immunome had a negative return on equity of 77.37% and a negative net margin of 1,687.08%.

Immunome Trading Down 1.7%

IMNM stock traded down $0.26 on Friday, hitting $15.24. The company had a trading volume of 1,665,412 shares, compared to its average volume of 1,235,020. Immunome has a 12-month low of $5.15 and a 12-month high of $17.87. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -5.17 and a beta of 1.96. The stock’s 50-day simple moving average is $12.83 and its 200 day simple moving average is $10.50.

Wall Street Analysts Forecast Growth

IMNM has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a research note on Wednesday, October 8th. Craig Hallum assumed coverage on Immunome in a report on Friday, September 5th. They issued a “buy” rating and a $26.00 target price on the stock. The Goldman Sachs Group began coverage on Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 target price on the stock. Guggenheim restated a “buy” rating and set a $25.00 price target on shares of Immunome in a report on Monday, August 25th. Finally, Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a research report on Saturday. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and an average target price of $23.20.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently modified their holdings of IMNM. BNP Paribas Financial Markets increased its position in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Immunome by 3.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock worth $2,612,000 after purchasing an additional 9,686 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Immunome by 44.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after buying an additional 14,398 shares during the last quarter. Finally, Creative Planning bought a new stake in Immunome during the second quarter valued at approximately $167,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.